CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease
The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...
TYO: 4523
Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval
Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...
Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab
Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...